about
Applications of 211At and 223Ra in targeted alpha-particle radiotherapyAstatine-211: production and availabilityTargeted radionuclide therapy with astatine-211: Oxidative dehalogenation of astatobenzoate conjugates.An alternative and expedient synthesis of radioiodinated 4-iodophenylalanine.Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals.Unconventional nuclides for radiopharmaceuticalsTreatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumabBisphosphonates as radionuclide carriers for imaging or systemic therapy.The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma.Unexpected Behavior of the Heaviest Halogen Astatine in the Nucleophilic Substitution of Aryliodonium Salts.Scrutinizing "Invisible" astatine: A challenge for modern density functionals.Advances on the Determination of the Astatine Pourbaix Diagram: Predomination of AtO(OH)2 (-) over At(-) in Basic Conditions.Targeted α Therapies for the Treatment of Bone Metastases.Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.Assessment of an effective quasirelativistic methodology designed to study astatine chemistry in aqueous solution
P2860
Q24610016-0C57FF21-D7B1-477F-8E52-F1B0AD925995Q27015038-BD8CD529-FD20-4675-BE66-901D06CD6598Q33746975-BAE0AA23-479F-4B0C-A394-C01AB7A4CA1DQ35147811-A0036B63-C523-4CB4-AF9E-DFAEBB430A3AQ35220659-CFAC8D4E-C351-4379-846F-93B87C073937Q35287836-16269895-7FC8-4611-92BE-F8B1B3216389Q37129181-2F6442E2-20B2-42BF-9ED2-84E420693477Q37289402-B342C0C0-77A5-4A3A-A583-22579095B412Q37924117-45B1D3EF-0524-4C43-8E1A-7BC03680E2C7Q38215613-ED4FBAF7-EBEB-4576-81BD-2305703189BFQ41027410-AD1F4F1D-ED04-47FA-B133-FB87ED00E886Q46566991-F1681123-3C1D-4A85-AED6-5D02B79D551DQ46610202-C4FCDC8B-C964-418E-95CD-624CADEB830AQ49271846-A34CDE9C-0E59-42F2-97A9-A7C2FC66273BQ55709954-696EA035-3237-4BF8-B88C-DAFF315FAA21Q56037968-C191CC66-414B-4588-93CF-028186F7F2A1
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Astatine Radiopharmaceuticals: Prospects and Problems
@ast
Astatine Radiopharmaceuticals: Prospects and Problems
@en
type
label
Astatine Radiopharmaceuticals: Prospects and Problems
@ast
Astatine Radiopharmaceuticals: Prospects and Problems
@en
prefLabel
Astatine Radiopharmaceuticals: Prospects and Problems
@ast
Astatine Radiopharmaceuticals: Prospects and Problems
@en
P2860
P1476
Astatine Radiopharmaceuticals: Prospects and Problems
@en
P2093
Ganesan Vaidyanathan
Michael R Zalutsky
P2860
P356
10.2174/1874471010801030177
P577
2008-09-01T00:00:00Z